Seguridad de los corticoides inhalados en la EPOC | Archivos de Bronconeumología
En algunos de estos procesos el debate sobre su protagonismo sigue abierto. Inhaled corticosteroids IC are used in chronic obstructive pulmonary disease COPD as these agents decrease the frequency of exacerbations and halt the impairment in health-related quality of life. The intimate mechanisms supporting their use and the dose that should be employed have not been sufficiently well established.
IC have adverse effects that are hardly described in guidelines for the management of COPD and are sometimes not even mentioned. These agents have been related to adverse effects in the upper airways, intraocular hypertension and glaucoma, loss of bone mass and fractures, adrenal suppression and, lately, with pneumonia. The debate on the role of CI in these processes is ongoing. However, given the growing frequency of the use of these drugs, awareness of their potential adverse effects is essential, especially since the pharmacodynamic characteristics of the distinct IC differ widely..
Arch Bronconeumol ;46 Supl 4: Seguridad de los corticoides inhalados en la EPOC. Safety of inhaled corticosteroids in COPD. However, given the growing frequency of the use of these drugs, awareness of their potential adverse effects is essential, especially since the pharmacodynamic characteristics of the distinct IC differ widely. Inhaled corticosteroids, Chronic obstructive pulmonary disease, Local and systemic adverse effects.
Arch Bronconeumol, 45 , pp. Arch Bronconeumol, 44 , pp. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2 , http: Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from to Chest, , pp. Use of medication and quality of life among patients with COPD. Respir Med, , pp.
The local side effects of inhaled corticosteroids: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol, , pp. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma.
Allergy, 61 , pp. Inhalational and topical steroids, and oral candidosis: Oral Dis, 7 , pp. Growth of Candida albicans in saliva: J Infect Dis, , pp. Growth and acid production of Candida species in human saliva supplemented with glucose. J Oral Pathol, 15 , pp. Dysphonia caused by inhaled steroids: Thorax, 38 , pp. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: Ann Allergy Asthma Immunol, 98 , pp. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma.
Oral candidiasis associated with inhaled corticosteroid use: Ann Allergy Asthma Immunol, 90 , pp. Epidemiol Rev, 17 , pp. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease update. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med, , pp. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts.
Eur Respir J, 27 , pp. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA, , pp. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol, 87 , pp.
The risk of cataract among users of inhaled steroids. Epidemiology, 12 , pp. Dose-response relationship of inhaled corticosteroids and cataracts: Respirology, 14 , pp. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology, , pp.
J Ocul Pharmacol Ther, 23 , pp. Glaucoma associated with metered-dose bronchodilator therapy. Respir Med, 95 , pp. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Inhaled corticosteroids, family history, and risk of glaucoma. Detection of glucocorticoid receptors in cultured human trabecular cells.
Invest Ophthalmol Vis Sci, 21 , pp. Predicting risk of osteoporotic fracture in men and women in England and Wales: BMJ, , pp. Endocr Rev, 29 , pp. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. Prevalence and progression of osteoporosis in patients with COPD: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Impact of long-term inhaled corticosteroid therapy on bone mineral density: Ann Allergy Asthma Immunol, 92 , pp. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J, 25 , pp. J Intern Med, , pp. Inhaled and nasal corticosteroid use and the risk of fracture.
Use of inhaled corticosteroids and the risk of fracture. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. QJM, , pp. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids.
Clin Exp Allergy, 38 , pp. Long-term therapy in COPD: Risk factors for community-acquired pneumonia in adults: Eur Respir J, 13 , pp. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: Arch Intern Med, , pp.
Budesonide and the risk of pneumonia: Lancet, , pp. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: Eur Respir J, 34 , pp. The epithelium as a target of glucocorticoid action in the treatment of asthma.
The instructive role of dendritic cells on T cell responses: Curr Opin Immunol, 13 , pp. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol, , pp. Survival after lung volume reduction in chronic obstructive pulmonary disease: